French software developer Dassault Systemes is in discussions to acquire ArisGlobal, a provider of drug-trial software, from the private equity firm Nordic Capital. According to the Financial Times, the deal is valued at approximately $2 billion.
The acquisition would represent Dassault Systemes' second-largest expansion into the life sciences software sector, following its $5.8 billion purchase of Medidata Solutions in 2019. The company has recently sought growth in data centers and AI technologies to offset a slowdown in its traditional automotive and industrial software markets.
As of Thursday, the companies involved have not issued official statements regarding the negotiations. The Financial Times noted that the discussions are ongoing and a final agreement has not yet been reached.